Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites

Representational image. Reuters[/caption]The US Food and Drug Administration (USFDA) issues an EIR to a company when an inspection is satisfactorily closed.The health regulator had inspected the company's Nagpur manufacturing facility between 6 January and 10 January, 2020, Lupin Ltd said in a statement."We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid dosage facility. We remain committed to enhancing compliance and quality standards across all our manufacturing sites," Lupin Managing Director Nilesh Gupta said.